Follow our progress

One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation

Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona

LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.

LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call